Greg Harrison
Stock Analyst at Scotiabank
(2.22)
# 2,710
Out of 4,893 analysts
89
Total ratings
44.93%
Success rate
-3.9%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Maintains: Sector Outperform | $32 → $35 | $14.25 | +145.61% | 2 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $298.41 | +5.56% | 4 | Jun 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Sector Outperform | $65 → $55 | $23.94 | +129.74% | 2 | Jun 2, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sector Outperform | $51 → $19 | $3.10 | +512.90% | 6 | May 28, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $36 → $37 | $14.14 | +161.67% | 6 | May 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $41 → $26 | $14.48 | +79.56% | 6 | May 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $19.37 | +3.25% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.38 | +9.09% | 3 | May 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $450 → $442 | $474.58 | -6.87% | 6 | May 6, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $74 → $71 | $39.58 | +79.38% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $52 → $55 | $46.05 | +19.44% | 6 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $338 → $342 | $320.00 | +6.88% | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $22.00 | +81.82% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $56.92 | +31.76% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $27 → $32 | $16.35 | +95.72% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $10.90 | +65.14% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $11.31 | +94.52% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $11.96 | +660.87% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.92 | +0.67% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.50 | +200.60% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $14.63 | +166.58% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.95 | +408.47% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $3.60 | -16.67% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.15 | +3,155.81% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $30.00 | -73.33% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $17.81 | +203.20% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $25.13 | +258.14% | 5 | Mar 14, 2022 |
Arcturus Therapeutics Holdings
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $14.25
Upside: +145.61%
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $298.41
Upside: +5.56%
Vera Therapeutics
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $23.94
Upside: +129.74%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.10
Upside: +512.90%
Liquidia
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $14.14
Upside: +161.67%
Keros Therapeutics
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $14.48
Upside: +79.56%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $19.37
Upside: +3.25%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.38
Upside: +9.09%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $474.58
Upside: -6.87%
Agios Pharmaceuticals
May 2, 2025
Maintains: Sector Outperform
Price Target: $74 → $71
Current: $39.58
Upside: +79.38%
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $46.05
Upside: +19.44%
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $320.00
Upside: +6.88%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $22.00
Upside: +81.82%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $56.92
Upside: +31.76%
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $27 → $32
Current: $16.35
Upside: +95.72%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $10.90
Upside: +65.14%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $11.31
Upside: +94.52%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $11.96
Upside: +660.87%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.92
Upside: +0.67%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.50
Upside: +200.60%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $14.63
Upside: +166.58%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.95
Upside: +408.47%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.60
Upside: -16.67%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.15
Upside: +3,155.81%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $30.00
Upside: -73.33%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $17.81
Upside: +203.20%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $25.13
Upside: +258.14%